Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Holtzman

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
African Journal of Infectious Diseases|October 1, 2021
INCIDENCE OF HIGH GRADE QTCF PROLONGATION AND ITS MANAGEMENT AMONG PATIENTS UNDERGOING TREATMENT FOR DRUG RESISTANT TUBERCULOSIS (DR-TB): CASE SERIESMeseret T Asfaw, David L Holtzman, Gene F Kwan, et al.
The American Journal of Emergency Medicine|July 17, 2012
Algid malaria treated with early goal-directed therapyDavid F Gaieski, Jason D Goldman, David L Holtzman, et al.
Nature Medicine|January 13, 2026
Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosisBrendan M Crowley, Helena I Boshoff, Aidan Boving, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
African Journal of Infectious Diseases|October 1, 2021
INCIDENCE OF HIGH GRADE QTCF PROLONGATION AND ITS MANAGEMENT AMONG PATIENTS UNDERGOING TREATMENT FOR DRUG RESISTANT TUBERCULOSIS (DR-TB): CASE SERIESMeseret T Asfaw, David L Holtzman, Gene F Kwan, et al.
The American Journal of Emergency Medicine|July 17, 2012
Algid malaria treated with early goal-directed therapyDavid F Gaieski, Jason D Goldman, David L Holtzman, et al.
Nature Medicine|January 13, 2026
Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosisBrendan M Crowley, Helena I Boshoff, Aidan Boving, et al.
Pageof 1